# PathMap Report Trace Context: #00000023
Hypothesis: Does misfolded TDP43 affect Retinal Ganglion Cell STMN2 ability to repair in a similar way as what how it was shown to affect motor neurons with cryptic mis-splicing?
Author: Joshua Dungan (PathMap.org)
License: 'THE GLOBAL HUMANITARIAN PROPRIETARY LICENSE (VERSION 1.0.1)' https://pathmap.org/license.pdf
Zenodo DOI: 10.5281/zenodo.21265319
Full provenance JSON trace: https://pathmap.org/download.php/?id=23
==================================================

SYSTEM NOTE: The eight-digit ID numbers (e.g., ID 12345678) used in citations below are PubMed ID numbers and can be loaded via https://pubmed.ncbi.nlm.nih.gov/{ID}/ for verification.

==================================================

## Primary Synthesis & Clinical Bottom-Line
This synthesis evaluates the mechanistic link between TDP-43 proteinopathy-induced STMN2 depletion and the regenerative capacity of Retinal Ganglion Cells. While TDP-43 pathology is well-documented to drive axonal regenerative failure in motor neurons through STMN2 cryptic splicing, the specific functional impact on RGC axonal repair ability remains inferred rather than directly observed in the provided literature.

## Plausibility Verdicts
- Evaluation 1: Evidence is robust for motor neurons and generalized CNS pathology, but direct evidence of this exact mechanism in RGCs remains a scientific gap.
- Evaluation 2: STMN2 depletion is a hallmark of TDP-43 dysfunction, but its role in RGC regeneration remains secondary to metabolic and inflammatory pathways identified in the literature.

## Novel & Overlooked Insights
- STMN2 is a highly labile, neurospecific protein whose levels are sensitive to acute stress through both TDP-43-dependent and independent pathways.
- Cryptic splicing of STMN2 is not limited to motor neurons; it is identified in the amygdala, hippocampus, and frontal cortex in AD-TDP and FTLD-TDP cases.
- Alternative polyadenylation (APA) acts as a parallel, understudied mechanism of STMN2 regulation, alongside canonical cryptic exon splicing.
- The depletion of STMN2 correlates with disease-associated biomarkers like neurofilament light chain in vitreous fluid.
- TDP-43 loss-of-function triggers a multi-gene splicing failure (UNC13A, KALRN, ATG4B) beyond just STMN2, creating a broader landscape of synaptic and excitability dysfunction.
- Nonsense-mediated decay (NMD) actively masks the true prevalence of STMN2 and other cryptic splicing events in bulk RNA-seq analyses, requiring NMD inhibition to fully appreciate the transcriptome disruption.
- Genetic strategies to restore STMN2 expression are being developed as a potential universal therapeutic for TDP-43 proteinopathies, regardless of the specific disease context.
- STMN2 is not only an ALS marker but also shows cryptic splicing in Alzheimer’s disease, where it correlates with TDP-43 pathology burden.
- The depletion of STMN2 protein can occur via TDP-43-independent mechanisms, such as stress granule formation and translation repression.
- SARM1 is identified as a key driver of axonal degeneration across multiple models of RGC loss, including glaucoma, suggesting it may be a convergent pathway for axonopathy.
- Therapeutic rescue of STMN2 levels can restore axonal regeneration capacity to wild-type levels in TDP-43-deficient motor neurons.
- Big tau isoforms are uniquely expressed in the visual system, providing a distinct cytoskeletal context compared to motor neurons.
- Some neurodegenerative disease markers like FUS or TDP-43 can influence the protein cargo of extracellular vesicles (EVs).
- STMN2 is not merely a marker of ALS; it is a critical "axon maintenance factor" whose depletion results in physical axonal caliber collapse.
- TDP-43 pathology is increasingly recognized as a "core integrative node" in Alzheimer’s disease, extending beyond the traditional amyloid-tau paradigm.
- The use of U7 snRNAs provides a potential "dual-targeting" therapeutic modality to correct the STMN2/UNC13A splicing defects simultaneously.
- Retinal ganglion cells exhibit a "highly active constitutive autophagy" which is essential for survival, yet this process often stalls in glaucomatous neurodegeneration.
- Mitochondrial transplantation (mitotherapy) is emerging as a novel strategy to restore metabolic integrity in RGCs, distinct from genetic splicing correction.
- Progranulin (PGRN) deficiency in brain organoids has been shown to spontaneously trigger TDP-43 pathology, linking systemic trophic factors to RNA-binding protein dysfunction.
- The "Molecular Zipper" hypothesis suggests that the earliest pathogenic event in TDP-43 proteinopathy is the unzipping of its physiological dimer structure.
- Short RNA chaperones have been identified as capable of stabilizing TDP-43, demonstrating that RNA-based therapeutic strategies are feasible to prevent pathogenic aggregation.

## Extracted Custom Discoveries
### Suggested Experiments
- Perform single-nuclei RNA sequencing (snRNA-seq) on retinal ganglion cells from TDP-43 mutant mouse models to assess STMN2 splicing profiles.
- Evaluate axonal regeneration capacity of RGCs derived from human iPSCs with TDP-43 knockdown vs. controls after optic nerve crush injury.
- 1. Perform single-nuclei RNA-sequencing (snRNA-seq) on retinal tissue from AD-TDP and ALS patients to identify if RGCs harbor STMN2 cryptic exons. 2. Compare axonal regenerative capacity in TDP-43-depleted versus control RGCs in iPSC-derived retinal organoids.
- Quantify STMN2 cryptic exon inclusion in RGCs following induced TDP-43 nuclear depletion via CRISPR/Cas9 or AAV-Cre.
- Evaluate axonal regeneration capacity of RGCs with and without ASO-mediated correction of STMN2 cryptic splicing in an ONC model.

### Suggested Studies
- Comparative proteomics of RGCs in FTLD-TDP patient postmortem tissue to quantify STMN2 protein depletion.
- Longitudinal study of vitreous STMN2 levels and retinal thinning in presymptomatic C9orf72 mutation carriers.
- 1. Longitudinal analysis of retinal integrity in trans-heterozygous Stmn2/TDP-43 mouse models. 2. Proteomic profiling of retinal ganglion cells stratified by TDP-43 pathological state.
- Comparative RNA-seq analysis of RGCs and motor neurons stratified by TDP-43 proteinopathy status to determine cell-type-specific sensitivity to STMN2 splicing defects.
- Longitudinal assessment of vitreous STMN2 protein levels in glaucoma patients with and without identified TDP-43 pathological markers.

### Swansons Literature Based Discovery Candidates
- TDP-43-induced STMN2 depletion impairs the regenerative potential of optic nerve fibers, potentially contributing to retinal pathology in ALS.
- TDP-43 loss of function leads to STMN2 mis-splicing and impaired axonal repair in motor neurons (Source: 40392845).
- Vitreous fluid in ALS/FTD patients shows reduced STMN2 levels, implying ocular-associated neurodegeneration (Source: 41180957).
- STMN2 protein, which is vital for microtubule dynamics and axonal regeneration.
- Since STMN2 is essential for axon regeneration in neurons and its levels are known to decline in the vitreous of TDP-43 pathology patients, it is mechanistically plausible that mis-splicing of STMN2 similarly inhibits the regenerative repair of retinal ganglion cell axons.
- Discovered Hypothesis (A to C): TDP-43-induced STMN2 deficiency in RGCs exacerbates SARM1-mediated distal axonopathy, making RGCs vulnerable to metabolic stress in early glaucoma or AD. - Literature A (Origin): The well-documented role of TDP-43 in inducing STMN2 cryptic splicing and axonal maintenance in motor neurons (ID: 36927019). - Literature C (Target): The SARM1-JNK signaling axis identified as a central switch for RGC axonal degeneration in glaucomatous and ischemic models (ID: 39499508). - The Intersecting Bridge B: SCG10 (STMN2) protein stability and its interaction with axonal transport or JNK signaling pathways. - Biological Rationale: STMN2 regulates microtubule dynamics and axonal transport. Its loss leads to axonal collapse. Given that SARM1-mediated degeneration is downstream of mitochondrial dysfunction and transport failure, it is plausible that STMN2 loss primes RGCs for a lower threshold of SARM1 activation during metabolic stress.
- Upregulation of the PI3K/Akt/Nrf2 pathway in RGCs can compensate for STMN2-mediated axonal fragility caused by early-stage TDP-43 dysfunction.
- TDP-43/STMN2 pathomechanism in motor neurons (Source: 40392845)
- PI3K/Akt/Nrf2 pathway neuroprotection in RGCs (Source: 42205897)
- Microtubule stability and oxidative stress resilience.
- The PI3K/Akt pathway promotes survival and mitochondrial health; given that STMN2 is essential for microtubule dynamics in axons, the PI3K/Akt pathway may provide a secondary metabolic support system that mitigates the downstream effects of STMN2 loss.

### Contradictions Between Evidences
- None identified in the current literature set.
- There is no explicit contradiction, but a divergence of focus: CNS research (ALS/FTD) focuses on nuclear TDP-43 loss causing cryptic splicing, while retinal research focuses on SARM1-mediated axonal degeneration in glaucoma, without explicitly linking the two in RGCs.
- None identified; literature consistently places STMN2 as a canonical TDP-43 target in the motor system, while RGC literature prioritizes mitochondrial and autophagic mechanisms.

### Repurposed Solutions
- Antisense oligonucleotides (ASOs) that correct STMN2 cryptic splicing in motor neurons could be repurposed for local intravitreal administration to preserve retinal ganglion cell health.
- The use of ASOs targeting STMN2 cryptic exons (ID: 41394711, 41573891) or U1 snRNAs could be repurposed for neuroprotection in retinal diseases characterized by TDP-43 pathology, such as glaucoma with comorbid LATE/AD features.
- The use of U7 snRNA-based gene therapies or small RNA chaperones, currently in development for ALS to restore STMN2, could be evaluated as a novel therapeutic strategy for glaucomatous neurodegeneration if cryptic splicing is confirmed in the RGC transcriptome.

## Evaluation Scoring Reference
All analyzed perspectives utilize a standardized 1-7 scoring framework:
- Alignment Score (1-7): How well does the evaluated claim factually align with the provided evidence set?
  [1 = Evidence proves claim strictly false, 2 = Evidence indicates the claim is impossible, 3 = Implausible, 4 = Neutral/Unrelated, 5 = Plausible, 6 = Evidence indicates inevitable, 7 = Evidence proves claim strictly true]
- Consilience Score (1-7): How consilient (in agreement) is the evidence set regarding this claim?
  [1 = Highly Conflicting/Disputed, 4 = Mixed, 7 = Unanimous Agreement]
- Confidence Score (1-7): Implied confidence of the research based on study design and depth.
  [1 = In Vitro/Animal/Preprint, 4 = Observational/Moderate, 7 = Meta-analysis/RCT]

## Evaluated Perspectives & Findings
### Perspective R1: Claim [Run1 Eval1 Synthesis] evaluated against Evidence [N/A]
- Alignment Score: 4/7
- Consilience Score: 7/7
- Directional Logic: High Score = SUPPORTS Original Claim
Even though this fact check looked at unique up-to-date abstracts, new evidence may refute this answer in the future. Although 'Zero Hallucinated Moneyshot Quotes' is programmatically enforced, AI is not always immune to inadvertently/erroneously misinterpreting data. This is not medical or professional advice, but instead, is an opinion calculated by AI based on the literature evaluated.

###[CLAIM EVALUATED AND ANSWER TO USER]
"Does misfolded TDP43 affect Retinal Ganglion Cell STMN2 ability to repair in a similar way as what how it was shown to affect motor neurons with cryptic mis-splicing?"

The current literature establishes that STMN2 is a critical protein for axonal maintenance and repair, and its expression is significantly reduced by TDP-43 dysfunction via cryptic splicing and polyadenylation across various neuronal types (including spinal motor neurons and cortical neurons). While the provided literature confirms that STMN2 depletion occurs in brain regions and spinal motor neurons, and notes that TDP-43-related changes can extend to ocular structures—specifically mentioning that vitreous STMN2 levels are diminished in TDP-43-positive cases—there is **no direct evidence** in the provided documents characterizing the specific effect of misfolded TDP-43 on the regenerative repair ability of Retinal Ganglion Cells (RGCs) via STMN2 mis-splicing. Therefore, the effect on RGCs specifically remains an evidential gap.

### [ABSTRACT & REWRITTEN CLAIM]
This synthesis evaluates the mechanistic link between TDP-43 proteinopathy-induced STMN2 depletion and the regenerative capacity of Retinal Ganglion Cells. While TDP-43 pathology is well-documented to drive axonal regenerative failure in motor neurons through STMN2 cryptic splicing, the specific functional impact on RGC axonal repair ability remains inferred rather than directly observed in the provided literature.

### [INTRODUCTION & JUSTIFICATION]
TDP-43 pathology is a defining pathological hallmark of multiple neurodegenerative diseases, including amyotrophic lateral sclerosis (ALS) and frontotemporal dementia (FTD). In almost all instances of ALS and other TDP-43 proteinopathies, stathmin-2 encoding mRNAs are cryptically spliced and polyadenylated in motor neurons, a pathogenic consequence of nuclear loss of function of the RNA binding protein TDP-43. This loss of nuclear function leads to the de-repression of cryptic exons in multiple transcripts, including STMN2, disrupting synaptic transmission and neurite outgrowth. Although the literature focuses heavily on motor neuron vulnerability, TDP-43-related changes can extend to ocular structures. Diminished vitreous STMN2 levels might indicate TDP-43-associated neurodegeneration. However, while STMN2 loss is known to lead to neurofilament-dependent axonal collapse, current research has not specifically delineated the RGC-specific regenerative failure as a direct consequence of STMN2 cryptic splicing in the same rigorous experimental detail as the motor neuron models.

### [DISCUSSION: NOVEL & OVERLOOKED]
*   STMN2 is a highly labile, neurospecific protein whose levels are sensitive to acute stress through both TDP-43-dependent and independent pathways.
*   Cryptic splicing of STMN2 is not limited to motor neurons; it is identified in the amygdala, hippocampus, and frontal cortex in AD-TDP and FTLD-TDP cases.
*   Alternative polyadenylation (APA) acts as a parallel, understudied mechanism of STMN2 regulation, alongside canonical cryptic exon splicing.
*   The depletion of STMN2 correlates with disease-associated biomarkers like neurofilament light chain in vitreous fluid.
*   TDP-43 loss-of-function triggers a multi-gene splicing failure (UNC13A, KALRN, ATG4B) beyond just STMN2, creating a broader landscape of synaptic and excitability dysfunction.
*   Nonsense-mediated decay (NMD) actively masks the true prevalence of STMN2 and other cryptic splicing events in bulk RNA-seq analyses, requiring NMD inhibition to fully appreciate the transcriptome disruption.
*   Genetic strategies to restore STMN2 expression are being developed as a potential universal therapeutic for TDP-43 proteinopathies, regardless of the specific disease context.

### [EVIDENCE, METHODOLOGY & CITATIONS]
1. ID: 40392845 - Application: Establishing the pathogenic mechanism of STMN2 depletion in ALS. - *"In almost all instances of ALS and other TDP-43 proteinopathies, stathmin-2 encoding mRNAs are cryptically spliced and polyadenylated in motor neurons, a pathogenic consequence of nuclear loss of function of the RNA binding protein TDP-43."*
2. ID: 41180957 - Application: Extending TDP-43 pathology observations to ocular structures. - *"Diminished vitreous STMN2 levels might indicate TDP-43-associated neurodegeneration."*
3. ID: 42343570 - Application: Defining the general role of STMN2 in neurodegeneration. - *"STMN2 is an abundant neurospecific protein dysregulated in neurodegenerative diseases such as amyotrophic lateral sclerosis (ALS)."*
4. ID: 41547996 - Application: Assessing STMN2 levels across brain regions. - *"Cytosolic STMN2 remained unchanged in all brain regions and decreased in the nuclear fraction of the Hip of RAD vs. SH."*
5. ID: 41490046 - Application: Linking STMN2 to broader TDP-43-driven splicing consequences. - *"lower VPS35 levels were associated with increased hyperphosphorylated TDP-43 and cryptic stathmin-2 RNA."*
6. ID: 41394711 - Application: Defining the functional impact of STMN2 cryptic splicing. - *"TDP-43 nuclear depletion in amyotrophic lateral sclerosis (ALS) causes de-repression of cryptic exons (CEs) in multiple transcripts, including UNC13A and STMN2, disrupting synaptic transmission and neurite outgrowth."*
7. ID: 40654715 - Application: Identifying alternative drivers of splicing pathology. - *"Surprisingly, the disruption to alternative APP splicing is mediated by a toxic gain of cytoplasmic TDP-43 function, rather than loss of its nuclear role."*
8. ID: 40291716 - Application: STMN2 involvement in extracellular vesicle release. - *"We establish that VAPB, VCP, and Stathmin-2 increase on EVs with trimer stabilization."*
9. ID: 39792557 - Application: Explaining the regulation of truncated TDP-43 isoforms. - *"sTDP43-encoding transcripts that escape NMD are rapidly degraded post-translationally via the proteasome and macroautophagy."*
10. ID: 39114608 - Application: Highlighting STMN2 as a critical marker. - *"Several critical cryptic splicing targets of TDP-43 have recently emerged, such as STMN2, UNC13A, and others."*
11. ID: 38941189 - Application: Temporal dynamics of STMN2 depletion. - *"Splicing changes are especially prominent and persisting for STMN2 RNA, and STMN2 protein becomes rapidly depleted early during stress."*
12. ID: 37605276 - Application: Observing cryptic RNA accumulation in AD-TDP. - *"We detected the accumulation of misspliced cryptic or skiptic RNAs of STMN2, KCNQ2, UNC13A, CAMK2B, and SYT7 in the amygdala and hippocampus of AD-TDP cases."*
13. ID: 38979232 - Application: Expanding the scope of TDP-43 cryptic targets. - *"TDP-43 loss of function induces multiple splicing changes, including a cryptic exon in the amyotrophic lateral sclerosis and fronto-temporal lobar degeneration risk gene UNC13A, leading to nonsense-mediated decay of UNC13A transcripts and loss of protein."*
14. ID: 37614226 - Application: Confirming the role of STMN2 in FTD/ALS. - *"STMN2 RNA is downregulated in FTD/ALS due to loss of TDP-43 activity and STMN2 loss is suggested to play a role in ALS pathogenesis."*
15. ID: 40667039 - Application: Defining nuclear clearance of TDP-43. - *"Nuclear clearance of TDP-43 disrupts its function and leads to the inclusion of aberrant cryptic exons."*
16. ID: 41120751 - Application: Discovering the APA mechanism of STMN2 regulation. - *"TDP-43 nuclear loss causes de-repression of cryptic exons, yet cryptic alternative polyadenylation (APA) events have been largely overlooked."*
17. ID: 39486415 - Application: Restoring STMN2 levels via SmD1 overexpression. - *"Crucially, overexpressing SmD1 in ALS iPSC-MNs restored CHMP7's cytoplasmic localization and corrected STMN2 splicing."*
18. ID: 37433765 - Application: Therapeutic strategy for STMN2 restoration. - *"Restoring expression of Stathmin-2: a novel strategy to treat TDP-43 proteinopathies."*
19. ID: 40967225 - Application: Evaluating STMN2 levels in brain transcriptomes. - *"Comparison with independent datasets from other cortical regions revealed consistent pathway alterations, including upregulation of STMN2 and NEFL across brain regions and subtypes."*
20. ID: 38940350 - Application: Contextualizing cryptic splicing in evolutionarily specialized regions. - *"Atrophy-correlated genes in FTLD-TDP showed greater overlap with TDP-43 cryptic splicing genes and genes with more numerous TDP-43 binding sites compared with atrophy-correlated genes in FTLD-tau."*



### Perspective R2: Claim [Run2 Eval1 Synthesis] evaluated against Evidence [N/A]
- Alignment Score: 5/7
- Consilience Score: 6/7
- Directional Logic: High Score = SUPPORTS Original Claim
Even though this fact check looked at unique up-to-date abstracts, new evidence may refute this answer in the future. Although 'Zero Hallucinated Moneyshot Quotes' is programmatically enforced, AI is not always immune to inadvertently/erroneously misinterpreting data. This is not medical or professional advice, but instead, is an opinion calculated by AI based on the literature evaluated.

###[CLAIM EVALUATED AND ANSWER TO USER]
Does misfolded TDP43 affect Retinal Ganglion Cell STMN2 ability to repair in a similar way as what how it was shown to affect motor neurons with cryptic mis-splicing?

The provided literature confirms that TDP-43 pathology and the resulting STMN2 cryptic splicing are hallmarks of neurodegeneration across the ALS/FTD/AD spectrum. While the literature extensively characterizes this process in motor neurons, the evidence regarding Retinal Ganglion Cells (RGCs) predominantly focuses on RGC loss in other pathologies (like glaucoma or familial dysautonomia). There is no explicit evidence in the provided literature stating that misfolded TDP-43 directly causes STMN2 cryptic splicing in RGCs specifically to drive their degeneration, though STMN2 is identified as a critical factor in the broader maintenance and regeneration of neuronal populations.

### [ABSTRACT & REWRITTEN CLAIM]
TDP-43 nuclear loss triggers the inclusion of cryptic exons in STMN2, leading to protein depletion and loss of axonal regenerative capacity in motor neurons. The query asks whether this mechanistic link exists in Retinal Ganglion Cells (RGCs). Current literature demonstrates TDP-43 pathology and STMN2 cryptic splicing are shared features in CNS neurodegeneration (ALS, FTD, AD) and highlights STMN2's role in axon maintenance; however, the specific demonstration of TDP-43-dependent STMN2 splicing in RGCs remains an area for future investigation.

### [INTRODUCTION & JUSTIFICATION]
In amyotrophic lateral sclerosis (ALS), the nuclear depletion of TDP-43 leads to the aberrant inclusion of a cryptic exon in the STMN2 pre-mRNA. This event causes translational repression and leads to the production of non-functional protein, ultimately impairing the axonal maintenance and regenerative functions of affected motor neurons. While the provided literature confirms that "The inclusion of cryptic exons in genes such as STMN2 and UNC13A has emerged as a hallmark of TDP-43 loss of function," the mechanistic application of this phenomenon in Retinal Ganglion Cells (RGCs) requires careful parsing. Studies establish that "Stathmin-2 (STMN2), a tubulin-binding protein essential for axon maintenance and repair, is profoundly depleted following loss of nuclear TDP-43 in neurodegenerative disease." However, the evidence for RGCs is largely derived from non-TDP-43 models, such as glaucoma or familial dysautonomia, where "Retinal pathology in FD involves progressive thinning of the retinal nerve fiber layer (RNFL), resulting from the degeneration of retinal ganglion cells (RGCs)." While "Stathmin2 (Stmn2) is a key target of TDP-43 regulation and aberrantly spliced Stmn2 mRNA is found in patients with ALS, frontotemporal dementia, and Alzheimer's Disease," the intersection between direct TDP-43 mis-splicing of STMN2 in RGCs and their degeneration is not explicitly mapped in the current data.

### [DISCUSSION: NOVEL & OVERLOOKED]
*   STMN2 is not only an ALS marker but also shows cryptic splicing in Alzheimer’s disease, where it correlates with TDP-43 pathology burden.
*   The depletion of STMN2 protein can occur via TDP-43-independent mechanisms, such as stress granule formation and translation repression.
*   SARM1 is identified as a key driver of axonal degeneration across multiple models of RGC loss, including glaucoma, suggesting it may be a convergent pathway for axonopathy.
*   Therapeutic rescue of STMN2 levels can restore axonal regeneration capacity to wild-type levels in TDP-43-deficient motor neurons.
*   Big tau isoforms are uniquely expressed in the visual system, providing a distinct cytoskeletal context compared to motor neurons.
*   Some neurodegenerative disease markers like FUS or TDP-43 can influence the protein cargo of extracellular vesicles (EVs).

### [EVIDENCE, METHODOLOGY & CITATIONS]
1. ID: 42254864 - Application: Defines the consensus on TDP-43 splicing targets. - "The inclusion of cryptic exons in genes such as STMN2 and UNC13A has emerged as a hallmark of TDP-43 loss of function"
2. ID: 42051315 - Application: Establishes the role of STMN2 in neuron repair. - "Stathmin-2 (STMN2), a tubulin-binding protein essential for axon maintenance and repair, is profoundly depleted following loss of nuclear TDP-43 in neurodegenerative disease"
3. ID: 39603486 - Application: Links STMN2/TDP-43 pathology across disease spectrum. - "Stathmin2 (Stmn2) is a key target of TDP-43 regulation and aberrantly spliced Stmn2 mRNA is found in patients with ALS, frontotemporal dementia, and Alzheimer's Disease"
4. ID: 42343570 - Application: Discusses stress-induced STMN2 depletion. - "human STMN2 protein level is extremely labile under acute high-magnitude stress"
5. ID: 42234776 - Application: Correlates splicing loss to function. - "TDP-43 reduction induces cryptic splicing and down-regulation of these genes, resulting in impaired excitability and synaptic transmission"
6. ID: 41996987 - Application: Discusses therapeutic gene replacement. - "Gene replacement therapy, which restores STMN2 expression, and antisense oligonucleotides (ASOs) targeting mutant transcripts show promise"
7. ID: 41651252 - Application: Discusses EV protein cargo. - "We identify which EV release pathway is affected by trimeric SOD1 using endocytosis and exocytosis inhibitors and analyze altered protein interaction pathways through co-immunoprecipitation and mass spectrometry proteomics. Our results show that VAPB, VCP, and Stathmin-2 increase on EVs when trimers are stabilized"
8. ID: 41573891 - Application: Evidence for snRNA therapy rescue. - "The engineered snRNAs restored normal pre-mRNA processing of both STMN2 and UNC13A transcripts despite TDP-43 loss of function, rescuing stathmin-2 protein levels in iPSC derived motor neurons, restoring their axonal regeneration capacity to wild-type levels"
9. ID: 41394711 - Application: Evidence for U7 snRNA efficacy. - "We developed a therapeutic U7 snRNA (tU7) approach that suppresses TDP-43-dependent mis-splicing, restores target gene expression, rescues neuronal functions in human iPSC-derived neurons"
10. ID: 40478310 - Application: Cryptic splicing identification in FTLD-TDP. - "we identified STMN2 and ARHGAP32 as genes with the most abundant and differentially expressed cryptic exons between FTLD-TDP patients and controls"
11. ID: 40275359 - Application: Regional brain variability in splicing. - "Extensive variation in RNA splicing was identified in the ALS brain, with 26-41% of alternatively spliced genes unique to a given brain region. This included detection of TDP-43-associated cryptic splicing events such as the STMN2 cryptic exon"
12. ID: 39486415 - Application: SMN/CHMP7 regulation. - "overexpressing SmD1 in ALS iPSC-MNs restored CHMP7's cytoplasmic localization and corrected STMN2 splicing"
13. ID: 39114608 - Application: General marker consensus. - "Several critical cryptic splicing targets of TDP-43 have recently emerged, such as STMN2, UNC13A, and others"
14. ID: 38443601 - Application: Temporal pathology link. - "nuclear TDP-43 pathology is an early event, occurring prior to cytoplasmic accumulation and is associated with loss-of-function measured by coincident STMN-2 cryptic splicing pathology"
15. ID: 38175301 - Application: AD pathology correlation. - "we identify both STMN2 and UNC13A cryptic exons in Alzheimer's disease patients, that correlate with TDP-43 pathology burden"
16. ID: 37996528 - Application: Mouse model pathology. - "Persistent stathmin-2 loss in adult mice results in pathologies found in ALS, including reduced interneurofilament spacing, axonal caliber collapse"
17. ID: 36927019 - Application: Mechanistic binding data. - "TDP-43 binding to a GU-rich region sterically blocked recognition of the cryptic 3' splice site in STMN2 pre-mRNA"
18. ID: 41121980 - Application: Quantifying CE dynamic range. - "design expands the dynamic range sevenfold: TDP-43 knockdown boosted STMN2 CE levels 1395-fold in differentiated SH-SY5Y neurons"
19. ID: 40501554 - Application: Multi-transcript CE inclusion data. - "ADNC+LATE-NC cases exhibited the highest burden of CE inclusion as quantified by measuring the levels of known TDP-43 regulated CEs within eight transcripts: STMN2, UNC13A, ELAVL3, KALRN, ARHGAP32, CAMK2B, PFKP, and SYT7"
20. ID: 37867934 - Application: RGC-specific markers. - "RNA-binding protein with multiple splicing (RBPMS) plays a crucial role in cardiac mesoderm specification and cardiovascular development, as well as being a typical marker for whole retinal ganglion cells (RGCs)."



### Perspective R3: Claim [Run3 Eval1 Synthesis] evaluated against Evidence [N/A]
- Alignment Score: 5/7
- Consilience Score: 6/7
- Directional Logic: High Score = SUPPORTS Original Claim
Even though this fact check looked at unique up-to-date abstracts, new evidence may refute this answer in the future. Although 'Zero Hallucinated Moneyshot Quotes' is programmatically enforced, AI is not always immune to inadvertently/erroneously misinterpreting data. This is not medical or professional advice, but instead, is an opinion calculated by AI based on the literature evaluated.

###[CLAIM EVALUATED AND ANSWER TO USER]
"Does misfolded TDP43 affect Retinal Ganglion Cell STMN2 ability to repair in a similar way as what how it was shown to affect motor neurons with cryptic mis-splicing?"

The provided literature confirms that TDP-43-dependent STMN2 cryptic splicing is a pervasive mechanism of neurodegeneration in TDP-43 proteinopathies. While STMN2 is established as an essential axonal maintenance protein in motor neurons, its involvement in retinal ganglion cell (RGC) repair is not explicitly detailed as a direct consequence of TDP-43-driven cryptic splicing within the provided literature. The evidence suggests that RGC survival is instead governed by distinct pathways—such as autophagy/mitophagy, neuroinflammation, and specific growth factor signaling—though the general link between TDP-43 pathology and STMN2 loss is universally acknowledged across ALS, FTD, and Alzheimer’s disease.

### [ABSTRACT & REWRITTEN CLAIM]
Scientific investigation into whether TDP-43-mediated STMN2 cryptic splicing disrupts axonal maintenance in retinal ganglion cells (RGCs) as it does in motor neurons. The synthesis of evidence indicates that while TDP-43 pathology is a core driver of STMN2 depletion across multiple neurodegenerative conditions, RGC-specific research predominantly focuses on mitochondrial flux, autophagy, and neuroinflammation as primary regenerative impediments.

### [INTRODUCTION & JUSTIFICATION]
The pathogenic mechanism of nuclear TDP-43 depletion has been rigorously characterized. "STMN2 is an abundant neurospecific protein dysregulated in neurodegenerative diseases such as amyotrophic lateral sclerosis (ALS)." The molecular hallmark of this loss is the aberrant splicing of pre-mRNA: "In almost all instances of ALS and other TDP-43 proteinopathies, stathmin-2 encoding mRNAs are cryptically spliced and polyadenylated in motor neurons, a pathogenic consequence of nuclear loss of function of the RNA binding protein TDP-43." This process effectively functions as a driver of degeneration: "aberrant splicing of Stathmin-2 (STMN2) pre-mRNA leads to the loss of axonal maintenance proteins in amyotrophic lateral sclerosis and frontotemporal dementia."

While this pathway is well-defined in the motor system, RGCs exhibit distinct vulnerability mechanisms. Studies indicate that RGC degeneration is profoundly influenced by mitochondrial quality control failure, where "Chronic IOP elevation led to increased mitochondrial accumulation, oxidative DNA damage, and impaired mitophagy/autophagy in glaucomatous retina." Therapeutic interventions in RGCs often target these metabolic axes rather than splicing correction. While "Diminished vitreous STMN2 levels might indicate TDP-43-associated neurodegeneration," suggesting a potential cross-system relevance, the literature does not yet explicitly demonstrate that TDP-43-driven cryptic splicing of STMN2 is a direct driver of RGC axon failure in the same mechanistic depth as in motor neurons.

### [DISCUSSION: NOVEL & OVERLOOKED]
*   STMN2 is not merely a marker of ALS; it is a critical "axon maintenance factor" whose depletion results in physical axonal caliber collapse.
*   TDP-43 pathology is increasingly recognized as a "core integrative node" in Alzheimer’s disease, extending beyond the traditional amyloid-tau paradigm.
*   The use of U7 snRNAs provides a potential "dual-targeting" therapeutic modality to correct the STMN2/UNC13A splicing defects simultaneously.
*   Retinal ganglion cells exhibit a "highly active constitutive autophagy" which is essential for survival, yet this process often stalls in glaucomatous neurodegeneration.
*   Mitochondrial transplantation (mitotherapy) is emerging as a novel strategy to restore metabolic integrity in RGCs, distinct from genetic splicing correction.
*   Progranulin (PGRN) deficiency in brain organoids has been shown to spontaneously trigger TDP-43 pathology, linking systemic trophic factors to RNA-binding protein dysfunction.
*   The "Molecular Zipper" hypothesis suggests that the earliest pathogenic event in TDP-43 proteinopathy is the unzipping of its physiological dimer structure.
*   Short RNA chaperones have been identified as capable of stabilizing TDP-43, demonstrating that RNA-based therapeutic strategies are feasible to prevent pathogenic aggregation.

### [EVIDENCE, METHODOLOGY & CITATIONS]
1. ID: 42343570 - "STMN2 is an abundant neurospecific protein dysregulated in neurodegenerative diseases such as amyotrophic lateral sclerosis (ALS)."
2. ID: 42254864 - "The inclusion of cryptic exons in genes such as STMN2 and UNC13A has emerged as a hallmark of TDP-43 loss of function, as demonstrated in TDP-43 knockdown models and postmortem analyses."
3. ID: 42234776 - "STMN2 and UNC13A have emerged as prominent TDP-43 splicing targets, but the broader impact of TDP-43-dependent cryptic splicing on neuronal function remains unclear."
4. ID: 41180957 - "Diminished vitreous STMN2 levels might indicate TDP-43-associated neurodegeneration."
5. ID: 40392845 - "In almost all instances of ALS and other TDP-43 proteinopathies, stathmin-2 encoding mRNAs are cryptically spliced and polyadenylated in motor neurons, a pathogenic consequence of nuclear loss of function of the RNA binding protein TDP-43."
6. ID: 37996528 - "Persistent stathmin-2 loss in adult mice results in pathologies found in ALS, including reduced interneurofilament spacing, axonal caliber collapse that drives tearing within outer myelin layers"
7. ID: 35767949 - "STMN2 knockout heterozygous mice, which better model the partial loss of STMN2 protein found in patients with ALS, display a slowly progressive, motor-selective neuropathy with functional deficits and NMJ denervation."
8. ID: 42143320 - "Chronic IOP elevation led to increased mitochondrial accumulation, oxidative DNA damage, and impaired mitophagy/autophagy in glaucomatous retina."
9. ID: 42359165 - "The identification of STMN2 as a downstream target of TDP-43 dysfunction has opened a potential TDP-43-downstream nucleic acid therapeutic avenue for sporadic ALS"
10. ID: 42337644 - "Outer nuclear layer (ONL) thinning has been identified in frontotemporal lobar degeneration (FTLD)"
11. ID: 38443601 - "nuclear TDP-43 pathology is an early event, occurring prior to cytoplasmic accumulation and is associated with loss-of-function measured by coincident STMN-2 cryptic splicing pathology."
12. ID: 41962593 - "aberrant splicing of Stathmin-2 (STMN2) pre-mRNA leads to the loss of axonal maintenance proteins in amyotrophic lateral sclerosis and frontotemporal dementia."
13. ID: 40501554 - "Notably, proteins significantly decreased under high CE burden included canonical STMN2, ELAVL3, and KALRN, as well as kinesin proteins that are genetically associated with amyotrophic lateral sclerosis."
14. ID: 42347120 - "Prion-like RBPs such as TDP-43 and FUS exhibit age-dependent mislocalisation, nuclear depletion, and cytoplasmic aggregation, contributing to splicing defects, impaired RNA transport, and neurodegeneration"
15. ID: 36927019 - "TDP-43 mislocalization results in cryptic splicing and polyadenylation of pre-messenger RNAs (pre-mRNAs) encoding stathmin-2 (also known as SCG10), a protein that is required for axonal regeneration."
16. ID: 42167675 - "TDP-43 mislocalization, post-translational modifications, and aggregation potentiate neuronal loss through disruption of RNA metabolism, nucleocytoplasmic transport, and protein homeostasis."
17. ID: 38562780 - "These findings demonstrate that partial loss of STMN2 significantly exacerbates TDP-43-associated phenotypes, suggesting that STMN2 restoration could ameliorate TDP-43 related disease before the onset of degeneration."
18. ID: 42135831 - "Elevated IL-1β expression was detected in vitreous amoeboid cells, and blockade of IL-1 signaling significantly reduced VHRFs, suppressed microglial migration, and delayed RGC loss."
19. ID: 42323105 - "We found that the necrotic rate increased in a time-dependent manner in RGCs following optic nerve injury, whereas apoptosis peaked at 7 days following nerve damage."
20. ID: 41951017 - "Strikingly, intravitreal delivery of mitochondria in an optic nerve crush model of adult mice enabled their integration into RGCs, improved survival and electrophysiological responses, and supported axonal regeneration across the lesion site."



## Logical Systems Map (Logical Gates)
- "TDP-43 pathology" -> "RNA Splicing"
- "RNA Splicing" -> "Stathmin 2"
- "TDP-43 pathology" -> "Vitreous Body"
- "DNA-Binding Protein-43" -> "Retinal Ganglion Cells"
- "Cell Nucleus" -> "RNA Splicing"
- "Stathmin 2" -> "Axonal Degeneration"
- "RNA Splicing" -> "Axons"
- "Axons" -> "Retinal Ganglion Cells"

## Verified Verbatim Quotes
- "Diminished vitreous STMN2 levels might indicate TDP-43-associated neurodegeneration."
- "STMN2 is an abundant neurospecific protein dysregulated in neurodegenerative diseases such as amyotrophic lateral sclerosis (ALS)."
- "Cytosolic STMN2 remained unchanged in all brain regions and decreased in the nuclear fraction of the Hip of RAD vs. SH."
- "lower VPS35 levels were associated with increased hyperphosphorylated TDP-43 and cryptic stathmin-2 RNA."
- "TDP-43 nuclear depletion in amyotrophic lateral sclerosis (ALS) causes de-repression of cryptic exons (CEs) in multiple transcripts, including UNC13A and STMN2, disrupting synaptic transmission and neurite outgrowth."
- "Surprisingly, the disruption to alternative APP splicing is mediated by a toxic gain of cytoplasmic TDP-43 function, rather than loss of its nuclear role."
- "In almost all instances of ALS and other TDP-43 proteinopathies, stathmin-2 encoding mRNAs are cryptically spliced and polyadenylated in motor neurons, a pathogenic consequence of nuclear loss of function of the RNA binding protein TDP-43."
- "We establish that VAPB, VCP, and Stathmin-2 increase on EVs with trimer stabilization."
- "sTDP43-encoding transcripts that escape NMD are rapidly degraded post-translationally via the proteasome and macroautophagy."
- "Several critical cryptic splicing targets of TDP-43 have recently emerged, such as STMN2, UNC13A, and others."
- "Splicing changes are especially prominent and persisting for STMN2 RNA, and STMN2 protein becomes rapidly depleted early during stress."
- "We detected the accumulation of misspliced cryptic or skiptic RNAs of STMN2, KCNQ2, UNC13A, CAMK2B, and SYT7 in the amygdala and hippocampus of AD-TDP cases."
- "In almost all instances of ALS and other TDP-43 proteinopathies, stathmin-2 encoding mRNAs are cryptically spliced and polyadenylated in motor neurons, a pathogenic consequence of nuclear loss of function of the RNA binding protein TDP-43."
- "Diminished vitreous STMN2 levels might indicate TDP-43-associated neurodegeneration."
- "STMN2 is an abundant neurospecific protein dysregulated in neurodegenerative diseases such as amyotrophic lateral sclerosis (ALS)."
- "Cytosolic STMN2 remained unchanged in all brain regions and decreased in the nuclear fraction of the Hip of RAD vs. SH."
- "lower VPS35 levels were associated with increased hyperphosphorylated TDP-43 and cryptic stathmin-2 RNA."
- "TDP-43 nuclear depletion in amyotrophic lateral sclerosis (ALS) causes de-repression of cryptic exons (CEs) in multiple transcripts, including UNC13A and STMN2, disrupting synaptic transmission and neurite outgrowth."
- "Surprisingly, the disruption to alternative APP splicing is mediated by a toxic gain of cytoplasmic TDP-43 function, rather than loss of its nuclear role."
- "We establish that VAPB, VCP, and Stathmin-2 increase on EVs with trimer stabilization."
- "sTDP43-encoding transcripts that escape NMD are rapidly degraded post-translationally via the proteasome and macroautophagy."
- "Several critical cryptic splicing targets of TDP-43 have recently emerged, such as STMN2, UNC13A, and others."
- "Splicing changes are especially prominent and persisting for STMN2 RNA, and STMN2 protein becomes rapidly depleted early during stress."
- "We detected the accumulation of misspliced cryptic or skiptic RNAs of STMN2, KCNQ2, UNC13A, CAMK2B, and SYT7 in the amygdala and hippocampus of AD-TDP cases."
- "TDP-43 loss of function induces multiple splicing changes, including a cryptic exon in the amyotrophic lateral sclerosis and fronto-temporal lobar degeneration risk gene UNC13A, leading to nonsense-mediated decay of UNC13A transcripts and loss of protein."
- "STMN2 RNA is downregulated in FTD/ALS due to loss of TDP-43 activity and STMN2 loss is suggested to play a role in ALS pathogenesis."
- "Nuclear clearance of TDP-43 disrupts its function and leads to the inclusion of aberrant cryptic exons."
- "TDP-43 nuclear loss causes de-repression of cryptic exons, yet cryptic alternative polyadenylation (APA) events have been largely overlooked."
- "Crucially, overexpressing SmD1 in ALS iPSC-MNs restored CHMP7's cytoplasmic localization and corrected STMN2 splicing."
- "Restoring expression of Stathmin-2: a novel strategy to treat TDP-43 proteinopathies."
- "In almost all instances of ALS and other TDP-43 proteinopathies, stathmin-2 encoding mRNAs are cryptically spliced and polyadenylated in motor neurons, a pathogenic consequence of nuclear loss of function of the RNA binding protein TDP-43."
- "Diminished vitreous STMN2 levels might indicate TDP-43-associated neurodegeneration."
- "STMN2 is an abundant neurospecific protein dysregulated in neurodegenerative diseases such as amyotrophic lateral sclerosis (ALS)."
- "Cytosolic STMN2 remained unchanged in all brain regions and decreased in the nuclear fraction of the Hip of RAD vs. SH."
- "lower VPS35 levels were associated with increased hyperphosphorylated TDP-43 and cryptic stathmin-2 RNA."
- "TDP-43 nuclear depletion in amyotrophic lateral sclerosis (ALS) causes de-repression of cryptic exons (CEs) in multiple transcripts, including UNC13A and STMN2, disrupting synaptic transmission and neurite outgrowth."
- "Surprisingly, the disruption to alternative APP splicing is mediated by a toxic gain of cytoplasmic TDP-43 function, rather than loss of its nuclear role."
- "We establish that VAPB, VCP, and Stathmin-2 increase on EVs with trimer stabilization."
- "sTDP43-encoding transcripts that escape NMD are rapidly degraded post-translationally via the proteasome and macroautophagy."
- "Several critical cryptic splicing targets of TDP-43 have recently emerged, such as STMN2, UNC13A, and others."
- "Splicing changes are especially prominent and persisting for STMN2 RNA, and STMN2 protein becomes rapidly depleted early during stress."
- "We detected the accumulation of misspliced cryptic or skiptic RNAs of STMN2, KCNQ2, UNC13A, CAMK2B, and SYT7 in the amygdala and hippocampus of AD-TDP cases."
- "TDP-43 loss of function induces multiple splicing changes, including a cryptic exon in the amyotrophic lateral sclerosis and fronto-temporal lobar degeneration risk gene UNC13A, leading to nonsense-mediated decay of UNC13A transcripts and loss of protein."
- "STMN2 RNA is downregulated in FTD/ALS due to loss of TDP-43 activity and STMN2 loss is suggested to play a role in ALS pathogenesis."
- "Nuclear clearance of TDP-43 disrupts its function and leads to the inclusion of aberrant cryptic exons."
- "TDP-43 nuclear loss causes de-repression of cryptic exons, yet cryptic alternative polyadenylation (APA) events have been largely overlooked."
- "Crucially, overexpressing SmD1 in ALS iPSC-MNs restored CHMP7's cytoplasmic localization and corrected STMN2 splicing."
- "Restoring expression of Stathmin-2: a novel strategy to treat TDP-43 proteinopathies."
- "Comparison with independent datasets from other cortical regions revealed consistent pathway alterations, including upregulation of STMN2 and NEFL across brain regions and subtypes."
- "Atrophy-correlated genes in FTLD-TDP showed greater overlap with TDP-43 cryptic splicing genes and genes with more numerous TDP-43 binding sites compared with atrophy-correlated genes in FTLD-tau."
- "human STMN2 protein level is extremely labile under acute high-magnitude stress"
- "The inclusion of cryptic exons in genes such as STMN2 and UNC13A has emerged as a hallmark of TDP-43 loss of function"
- "TDP-43 reduction induces cryptic splicing and down-regulation of these genes, resulting in impaired excitability and synaptic transmission"
- "Stathmin-2 (STMN2), a tubulin-binding protein essential for axon maintenance and repair, is profoundly depleted following loss of nuclear TDP-43 in neurodegenerative disease"
- "Gene replacement therapy, which restores STMN2 expression, and antisense oligonucleotides (ASOs) targeting mutant transcripts show promise"
- "We identify which EV release pathway is affected by trimeric SOD1 using endocytosis and exocytosis inhibitors and analyze altered protein interaction pathways through co-immunoprecipitation and mass spectrometry proteomics. Our results show that VAPB, VCP, and Stathmin-2 increase on EVs when trimers are stabilized"
- "The engineered snRNAs restored normal pre-mRNA processing of both STMN2 and UNC13A transcripts despite TDP-43 loss of function, rescuing stathmin-2 protein levels in iPSC derived motor neurons, restoring their axonal regeneration capacity to wild-type levels"
- "We developed a therapeutic U7 snRNA (tU7) approach that suppresses TDP-43-dependent mis-splicing, restores target gene expression, rescues neuronal functions in human iPSC-derived neurons"
- "we identified STMN2 and ARHGAP32 as genes with the most abundant and differentially expressed cryptic exons between FTLD-TDP patients and controls"
- "Extensive variation in RNA splicing was identified in the ALS brain, with 26-41% of alternatively spliced genes unique to a given brain region. This included detection of TDP-43-associated cryptic splicing events such as the STMN2 cryptic exon"
- "Stathmin2 (Stmn2) is a key target of TDP-43 regulation and aberrantly spliced Stmn2 mRNA is found in patients with ALS, frontotemporal dementia, and Alzheimer's Disease"
- "overexpressing SmD1 in ALS iPSC-MNs restored CHMP7's cytoplasmic localization and corrected STMN2 splicing"
- "Several critical cryptic splicing targets of TDP-43 have recently emerged, such as STMN2, UNC13A, and others"
- "nuclear TDP-43 pathology is an early event, occurring prior to cytoplasmic accumulation and is associated with loss-of-function measured by coincident STMN-2 cryptic splicing pathology"
- "we identify both STMN2 and UNC13A cryptic exons in Alzheimer's disease patients, that correlate with TDP-43 pathology burden"
- "Persistent stathmin-2 loss in adult mice results in pathologies found in ALS, including reduced interneurofilament spacing, axonal caliber collapse"
- "TDP-43 binding to a GU-rich region sterically blocked recognition of the cryptic 3' splice site in STMN2 pre-mRNA"
- "human STMN2 protein level is extremely labile under acute high-magnitude stress"
- "The inclusion of cryptic exons in genes such as STMN2 and UNC13A has emerged as a hallmark of TDP-43 loss of function"
- "TDP-43 reduction induces cryptic splicing and down-regulation of these genes, resulting in impaired excitability and synaptic transmission"
- "Stathmin-2 (STMN2), a tubulin-binding protein essential for axon maintenance and repair, is profoundly depleted following loss of nuclear TDP-43 in neurodegenerative disease"
- "Gene replacement therapy, which restores STMN2 expression, and antisense oligonucleotides (ASOs) targeting mutant transcripts show promise"
- "We identify which EV release pathway is affected by trimeric SOD1 using endocytosis and exocytosis inhibitors and analyze altered protein interaction pathways through co-immunoprecipitation and mass spectrometry proteomics. Our results show that VAPB, VCP, and Stathmin-2 increase on EVs when trimers are stabilized"
- "The engineered snRNAs restored normal pre-mRNA processing of both STMN2 and UNC13A transcripts despite TDP-43 loss of function, rescuing stathmin-2 protein levels in iPSC derived motor neurons, restoring their axonal regeneration capacity to wild-type levels"
- "We developed a therapeutic U7 snRNA (tU7) approach that suppresses TDP-43-dependent mis-splicing, restores target gene expression, rescues neuronal functions in human iPSC-derived neurons"
- "we identified STMN2 and ARHGAP32 as genes with the most abundant and differentially expressed cryptic exons between FTLD-TDP patients and controls"
- "Extensive variation in RNA splicing was identified in the ALS brain, with 26-41% of alternatively spliced genes unique to a given brain region. This included detection of TDP-43-associated cryptic splicing events such as the STMN2 cryptic exon"
- "Stathmin2 (Stmn2) is a key target of TDP-43 regulation and aberrantly spliced Stmn2 mRNA is found in patients with ALS, frontotemporal dementia, and Alzheimer's Disease"
- "overexpressing SmD1 in ALS iPSC-MNs restored CHMP7's cytoplasmic localization and corrected STMN2 splicing"
- "Several critical cryptic splicing targets of TDP-43 have recently emerged, such as STMN2, UNC13A, and others"
- "nuclear TDP-43 pathology is an early event, occurring prior to cytoplasmic accumulation and is associated with loss-of-function measured by coincident STMN-2 cryptic splicing pathology"
- "we identify both STMN2 and UNC13A cryptic exons in Alzheimer's disease patients, that correlate with TDP-43 pathology burden"
- "Persistent stathmin-2 loss in adult mice results in pathologies found in ALS, including reduced interneurofilament spacing, axonal caliber collapse"
- "TDP-43 binding to a GU-rich region sterically blocked recognition of the cryptic 3' splice site in STMN2 pre-mRNA"
- "design expands the dynamic range sevenfold: TDP-43 knockdown boosted STMN2 CE levels 1395-fold in differentiated SH-SY5Y neurons"
- "ADNC+LATE-NC cases exhibited the highest burden of CE inclusion as quantified by measuring the levels of known TDP-43 regulated CEs within eight transcripts: STMN2, UNC13A, ELAVL3, KALRN, ARHGAP32, CAMK2B, PFKP, and SYT7"
- "The inclusion of cryptic exons in genes such as STMN2 and UNC13A has emerged as a hallmark of TDP-43 loss of function"
- "Stathmin-2 (STMN2), a tubulin-binding protein essential for axon maintenance and repair, is profoundly depleted following loss of nuclear TDP-43 in neurodegenerative disease"
- "Stathmin2 (Stmn2) is a key target of TDP-43 regulation and aberrantly spliced Stmn2 mRNA is found in patients with ALS, frontotemporal dementia, and Alzheimer's Disease"
- "human STMN2 protein level is extremely labile under acute high-magnitude stress"
- "TDP-43 reduction induces cryptic splicing and down-regulation of these genes, resulting in impaired excitability and synaptic transmission"
- "Gene replacement therapy, which restores STMN2 expression, and antisense oligonucleotides (ASOs) targeting mutant transcripts show promise"
- "We identify which EV release pathway is affected by trimeric SOD1 using endocytosis and exocytosis inhibitors and analyze altered protein interaction pathways through co-immunoprecipitation and mass spectrometry proteomics. Our results show that VAPB, VCP, and Stathmin-2 increase on EVs when trimers are stabilized"
- "The engineered snRNAs restored normal pre-mRNA processing of both STMN2 and UNC13A transcripts despite TDP-43 loss of function, rescuing stathmin-2 protein levels in iPSC derived motor neurons, restoring their axonal regeneration capacity to wild-type levels"
- "We developed a therapeutic U7 snRNA (tU7) approach that suppresses TDP-43-dependent mis-splicing, restores target gene expression, rescues neuronal functions in human iPSC-derived neurons"
- "we identified STMN2 and ARHGAP32 as genes with the most abundant and differentially expressed cryptic exons between FTLD-TDP patients and controls"
- "Extensive variation in RNA splicing was identified in the ALS brain, with 26-41% of alternatively spliced genes unique to a given brain region. This included detection of TDP-43-associated cryptic splicing events such as the STMN2 cryptic exon"
- "overexpressing SmD1 in ALS iPSC-MNs restored CHMP7's cytoplasmic localization and corrected STMN2 splicing"
- "Several critical cryptic splicing targets of TDP-43 have recently emerged, such as STMN2, UNC13A, and others"
- "nuclear TDP-43 pathology is an early event, occurring prior to cytoplasmic accumulation and is associated with loss-of-function measured by coincident STMN-2 cryptic splicing pathology"
- "we identify both STMN2 and UNC13A cryptic exons in Alzheimer's disease patients, that correlate with TDP-43 pathology burden"
- "Persistent stathmin-2 loss in adult mice results in pathologies found in ALS, including reduced interneurofilament spacing, axonal caliber collapse"
- "TDP-43 binding to a GU-rich region sterically blocked recognition of the cryptic 3' splice site in STMN2 pre-mRNA"
- "design expands the dynamic range sevenfold: TDP-43 knockdown boosted STMN2 CE levels 1395-fold in differentiated SH-SY5Y neurons"
- "ADNC+LATE-NC cases exhibited the highest burden of CE inclusion as quantified by measuring the levels of known TDP-43 regulated CEs within eight transcripts: STMN2, UNC13A, ELAVL3, KALRN, ARHGAP32, CAMK2B, PFKP, and SYT7"
- "RNA-binding protein with multiple splicing (RBPMS) plays a crucial role in cardiac mesoderm specification and cardiovascular development, as well as being a typical marker for whole retinal ganglion cells (RGCs)."
- "STMN2 is an abundant neurospecific protein dysregulated in neurodegenerative diseases such as amyotrophic lateral sclerosis (ALS)."
- "The inclusion of cryptic exons in genes such as STMN2 and UNC13A has emerged as a hallmark of TDP-43 loss of function, as demonstrated in TDP-43 knockdown models and postmortem analyses."
- "STMN2 and UNC13A have emerged as prominent TDP-43 splicing targets, but the broader impact of TDP-43-dependent cryptic splicing on neuronal function remains unclear."
- "Diminished vitreous STMN2 levels might indicate TDP-43-associated neurodegeneration."
- "In almost all instances of ALS and other TDP-43 proteinopathies, stathmin-2 encoding mRNAs are cryptically spliced and polyadenylated in motor neurons, a pathogenic consequence of nuclear loss of function of the RNA binding protein TDP-43."
- "Persistent stathmin-2 loss in adult mice results in pathologies found in ALS, including reduced interneurofilament spacing, axonal caliber collapse that drives tearing within outer myelin layers"
- "STMN2 knockout heterozygous mice, which better model the partial loss of STMN2 protein found in patients with ALS, display a slowly progressive, motor-selective neuropathy with functional deficits and NMJ denervation."
- "Chronic IOP elevation led to increased mitochondrial accumulation, oxidative DNA damage, and impaired mitophagy/autophagy in glaucomatous retina."
- "The identification of STMN2 as a downstream target of TDP-43 dysfunction has opened a potential TDP-43-downstream nucleic acid therapeutic avenue for sporadic ALS"
- "Outer nuclear layer (ONL) thinning has been identified in frontotemporal lobar degeneration (FTLD)"
- "nuclear TDP-43 pathology is an early event, occurring prior to cytoplasmic accumulation and is associated with loss-of-function measured by coincident STMN-2 cryptic splicing pathology."
- "aberrant splicing of Stathmin-2 (STMN2) pre-mRNA leads to the loss of axonal maintenance proteins in amyotrophic lateral sclerosis and frontotemporal dementia."
- "Notably, proteins significantly decreased under high CE burden included canonical STMN2, ELAVL3, and KALRN, as well as kinesin proteins that are genetically associated with amyotrophic lateral sclerosis."
- "Prion-like RBPs such as TDP-43 and FUS exhibit age-dependent mislocalisation, nuclear depletion, and cytoplasmic aggregation, contributing to splicing defects, impaired RNA transport, and neurodegeneration"
- "TDP-43 mislocalization results in cryptic splicing and polyadenylation of pre-messenger RNAs (pre-mRNAs) encoding stathmin-2 (also known as SCG10), a protein that is required for axonal regeneration."
- "TDP-43 mislocalization, post-translational modifications, and aggregation potentiate neuronal loss through disruption of RNA metabolism, nucleocytoplasmic transport, and protein homeostasis."
- "These findings demonstrate that partial loss of STMN2 significantly exacerbates TDP-43-associated phenotypes, suggesting that STMN2 restoration could ameliorate TDP-43 related disease before the onset of degeneration."
- "Elevated IL-1β expression was detected in vitreous amoeboid cells, and blockade of IL-1 signaling significantly reduced VHRFs, suppressed microglial migration, and delayed RGC loss."
- "STMN2 is an abundant neurospecific protein dysregulated in neurodegenerative diseases such as amyotrophic lateral sclerosis (ALS)."
- "The inclusion of cryptic exons in genes such as STMN2 and UNC13A has emerged as a hallmark of TDP-43 loss of function, as demonstrated in TDP-43 knockdown models and postmortem analyses."
- "STMN2 and UNC13A have emerged as prominent TDP-43 splicing targets, but the broader impact of TDP-43-dependent cryptic splicing on neuronal function remains unclear."
- "Diminished vitreous STMN2 levels might indicate TDP-43-associated neurodegeneration."
- "In almost all instances of ALS and other TDP-43 proteinopathies, stathmin-2 encoding mRNAs are cryptically spliced and polyadenylated in motor neurons, a pathogenic consequence of nuclear loss of function of the RNA binding protein TDP-43."
- "Persistent stathmin-2 loss in adult mice results in pathologies found in ALS, including reduced interneurofilament spacing, axonal caliber collapse that drives tearing within outer myelin layers"
- "STMN2 knockout heterozygous mice, which better model the partial loss of STMN2 protein found in patients with ALS, display a slowly progressive, motor-selective neuropathy with functional deficits and NMJ denervation."
- "Chronic IOP elevation led to increased mitochondrial accumulation, oxidative DNA damage, and impaired mitophagy/autophagy in glaucomatous retina."
- "The identification of STMN2 as a downstream target of TDP-43 dysfunction has opened a potential TDP-43-downstream nucleic acid therapeutic avenue for sporadic ALS"
- "Outer nuclear layer (ONL) thinning has been identified in frontotemporal lobar degeneration (FTLD)"
- "nuclear TDP-43 pathology is an early event, occurring prior to cytoplasmic accumulation and is associated with loss-of-function measured by coincident STMN-2 cryptic splicing pathology."
- "aberrant splicing of Stathmin-2 (STMN2) pre-mRNA leads to the loss of axonal maintenance proteins in amyotrophic lateral sclerosis and frontotemporal dementia."
- "Notably, proteins significantly decreased under high CE burden included canonical STMN2, ELAVL3, and KALRN, as well as kinesin proteins that are genetically associated with amyotrophic lateral sclerosis."
- "Prion-like RBPs such as TDP-43 and FUS exhibit age-dependent mislocalisation, nuclear depletion, and cytoplasmic aggregation, contributing to splicing defects, impaired RNA transport, and neurodegeneration"
- "TDP-43 mislocalization results in cryptic splicing and polyadenylation of pre-messenger RNAs (pre-mRNAs) encoding stathmin-2 (also known as SCG10), a protein that is required for axonal regeneration."
- "TDP-43 mislocalization, post-translational modifications, and aggregation potentiate neuronal loss through disruption of RNA metabolism, nucleocytoplasmic transport, and protein homeostasis."
- "These findings demonstrate that partial loss of STMN2 significantly exacerbates TDP-43-associated phenotypes, suggesting that STMN2 restoration could ameliorate TDP-43 related disease before the onset of degeneration."
- "Elevated IL-1β expression was detected in vitreous amoeboid cells, and blockade of IL-1 signaling significantly reduced VHRFs, suppressed microglial migration, and delayed RGC loss."
- "We found that the necrotic rate increased in a time-dependent manner in RGCs following optic nerve injury, whereas apoptosis peaked at 7 days following nerve damage."
- "Strikingly, intravitreal delivery of mitochondria in an optic nerve crush model of adult mice enabled their integration into RGCs, improved survival and electrophysiological responses, and supported axonal regeneration across the lesion site."